Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.37 |
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524327 | 0.86 | CNR1 (0.38) | CNR1CNR2P2RX3P2RX2ANO1 | |
| SCHEMBL5266481 | 0.85 | PPP1CA (0.41) | P2RX3P2RX2KDM5AKDM4CKDM5B | |
| SCHEMBL5525584 | 0.83 | CNR1 (0.41) | CNR1CNR2ANO1SMPD1 | |
| SCHEMBL5533912 | 0.83 | CNR1 (0.51) | CNR1CNR2ANO1RIPK1 | |
| SCHEMBL5977928 | 0.82 | CNR1 (0.47) | CNR1CNR2ANO1SMPD1SYK | |
| SCHEMBL5269059 | 0.80 | CA9 (0.43) | — | |
| SCHEMBL5522031 | 0.78 | CNR1 (0.52) | CNR1CNR2ANO1SMPD1RIPK1 | |
| SCHEMBL14529223 | 0.78 | MGLL (0.43) | KDM4C | |
| SCHEMBL5526505 | 0.76 | CNR1 (0.41) | CNR1CNR2P2RX3P2RX2 | |
| SCHEMBL5525851 | 0.76 | ALOX5 (0.37) | CNR1CNR2ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | CNR1 76/4885CNR2 43/4885P2RX3 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.